Le Lézard
Classified in: Health
Subjects: CCA, BFA, PET, FVT

Aratana Therapeutics to Report Third Quarter 2017 Financial Results



LEAWOOD, Kan., Oct. 5, 2017 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative therapeutics for dogs and cats, will host a live conference call on Friday, November 3, 2017 at 8:30 a.m. ET to discuss financial results from the third quarter ended September 30, 2017.

Aratana Therapeutics logo

Interested participants and investors may access the audio webcast or use the conference call dial-in:

     1 (866) 364-3820 (U.S.) 
     1 (855) 669-9657 (Canada)
     1 (412) 902-4210 (International)

A replay of the third quarter results teleconference will be available the same day of the event by approximately 11 a.m. ET and an audio webcast will be accessible for 90 days in the Aratana Investor Room. For a replay of the call, use the below dial-in and conference ID 10112622:

     1 (877) 344-7529 (U.S.) 
     1 (855) 669-9658 (Canada
     1 (412) 317-0088 (International)

About Aratana Therapeutics
Aratana Therapeutics is a pet therapeutics company focused on licensing, developing and commercializing innovative therapeutics for dogs and cats. Aratana believes that it can leverage the investment in the human biopharmaceutical industry to bring therapeutics to dogs and cats in a capital and time efficient manner. The company's pipeline includes therapeutic candidates for the potential treatment of pain, inappetence, viral diseases, allergy, cancer and other serious medical conditions. Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets' medical needs safely and effectively, resulting in longer and improved quality of life for pets. For more information, please visit www.aratana.com.

Contacts
For investor inquires:
Craig Tooman
ctooman@aratana.com 
(913) 353-1026

For media inquiries:
Rachel Reiff
rreiff@aratana.com 
(913) 353-1050

SOURCE Aratana Therapeutics, Inc.


These press releases may also interest you

at 11:25
When it comes to providing quality education to its members, Mississippi Hospital Association (MHA) feels there is no such thing as too much, which is why they have invited Wound Care Education Institute® (WCEI®) to Madison, Mississippi to teach the...

at 11:12
Paragon Bioservices, a global leader in the manufacturing of biopharmaceuticals and vaccines, is proud to be a recipient of BBJ's Fast 50 Award this year.  On November 29th, the Baltimore Business Journal hosted the...

at 11:11
There are 50 key biotechnology companies that are shaping the biotherapeutics market in 2017 and beyond, according to Kalorama Information. The biotherapeutics sector, composed of biopharmaceuticals and biotechnology, is the fastest growing sector in...

at 11:05
The Center for Plain Language is speaking out against proposed changes to the Centers for Disease Control and Prevention's (CDC) communication rules. On Friday, December 15, the Washington Post reported that the Trump administration is forbidding CDC...

at 11:05
Musculoskeletal Clinical Regulatory Advisers, LLC (MCRA), a leading advisory firm and Clinical Research Organization (CRO) to the medical device industry, is pleased to announce that it delivered an informational presentation about United States...

at 11:03
Further to a December 5th press release announcing plans to establish a 40,000 m2 facility in the Danish city of Odense, Spectrum Cannabis Denmark has been issued a cannabis production licence by Laegemiddelstyrelsen, Denmark's Medicines Agency....




News published on 5 october 2017 at 16:30 and distributed by: